Analyst Research and Recommendations: Enzo Biochem, Inc. (ENZ)), Pennsylvania Real Estate Investment Trust (PEI))

Enzo Biochem, Inc. (NYSE:ENZ)) tinted gains of +0.79% (+0.02 points) to US$2.54. The volume of 0.52 Million shares climbed down over an trading activity of 205.16 Million shares. EPS ratio determined by looking at last 12 month figures is -0.33. Over the same time span, the stock marked US$8.71 as its best level and the lowest price reached was US$2.4. The corporation has a market cap of US$123.57 Million.

Enzo Biochem, Inc. (NYSE:ENZ))’s earnings per share has been growing at a 13.8 percent rate over the past 5 year when average revenue increase was noted as 2.2 percent. The return on equity ratio or ROE stands at -18.9 percent while most common profitability ratio return on investment (ROI) was -13.5 percent. The company’s institutional ownership is monitored at 70.1 percent. The company’s net profit margin has achieved the current level of -15.9 percent and possesses 39.8 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Pennsylvania Real Estate Investment Trust (NYSE:PEI)) is worth US$436.29 Million and has recently risen 7.75% to US$6.12. The latest exchange of 1.85 Million shares is above its average trading activity of 1.05 Million shares. The day began at US$5.7 but the price moved to US$5.6 at one point during the trading and finally capitulating to a session high of US$6.14. The stock tapped a 52-week high of US$12.52 while the mean 12-month price target for the shares is US$9.25.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.78, and a price to sales ratio of 1.19. For the past 5 years, the company’s revenue has grown -2.6%, while the company’s earnings per share has grown 0.8%. With an institutional ownership near 95.4%, it carries an earnings per share ratio of -0.8.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 5 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 3 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.38.